Zephyr Energy Share News (ZPHR)

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday.

----------

AIM - WINNERS

----------

Thor Explorations Ltd, up 16% at 25.5 pence, 12-month range 13.5p-26p. The Vancouver-based gold miner with projects in West Africa reports surge in net profit for 2024 to USD91.1 million from USD10.8 million in 2023. Revenue increased to USD193.1 million from USD141.2 million. Company also announces its maiden dividend, committing to a dividend policy of at least 1.25 Canadian cents per share per quarter. Says it sold 84,965 ounces of gold, up from 73,356 ounces, with the average gold price rising to USD2,288 per ounce from USD1,907. Also, Thor "has fully settled its senior debt obligations" having made the final USD4.1 million payment towards its senior debt facility with Africa Finance Corp. For 2025, it guides for production between 85,000 and 95,000 ounces with AISC guidance of between USD800 and USD1,000 per ounce.

----------

Zephyr Energy PLC, up 13% at 3.6 pence, 12-month range 2.4p-5.75p. The Rocky Mountain region-focused oil and gas company updates on completion and production testing operations on the State 36-2 LNW-CC-R well at its project in the Paradox Basin, Utah. Says the well's lateral portion was perforated with 98 cuts across 16 stages targeting optimised sections of the reservoir over the last two weeks. Adds that the pressure response suggests the wellbore has good connections to the highly pressured Cane Creek reservoir. Looking ahead, Zephyr "will shortly commence production testing" with plans to deploy a fibre optic cable which will gather data to help it "further understand the production capacity of the reservoir and to optimise stimulation techniques for future operations". "The company continues to anticipate that initial production test results will be available by the end of April 2025, subject to weather and vendor schedules," Zephyr notes.

----------

AIM - LOSERS

----------

Belluscura PLC, down 48% at 0.65p, 12-month range 0.65p-17.25p. The London-based medical device developer has withdrawn its guidance for 2025, citing US tariffs on imports. It highlights that a "significant proportion" of its portable oxygen concentrators, raw materials and component parts are made in China. Such products are now facing a 54% tariff when imported to the US. Belluscura expects to make a further announcement once it has been able to better assess the situation.

----------

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.